Dr Mark Guthridge - Researcher Profile

Biography

Dr. Mark Guthridge completed his Ph.D studies at Monash University after which he took up a postdoctoral position at New York University Medical Centre as a Darland Research Fellow. He returned to the Institute of Medical and Veterinary Science, Adelaide Australia in 1998 and was awarded a Peter Nelson Leukaemia Research Fellowship to examine molecular approaches for the therapeutic targeting of acute myeloid leukemic (AML) cells. In 2011 Dr. Guthridge moved his laboratory to the Division of Blood Cancers at the Australian Centre for Blood Diseases (ACBD) located on the Alfred Medical Research and Education Precinct (AMREP) in Melbourne.

Since 2000, Dr. Guthridge's lab has received continual funding from International (NIH, AICR), National (NH&MRC, LFA) and State agencies (Cancer Council of SA).  His work has been published in top-tier journals including Cell, Molecular Cell, Cell Stem Cell and EMBO J as well as leading specialist cancer/hemopoietic journals such as Blood, Leukemia and Cancer Research. Dr. Guthridge regularly serves of NH&MRC GRPs and is co-convenor of the New Directions in Leukaemia Research (NDLR) conference held biennially on the Sunshine Coast, QLD.

Dr. Guthridge’s research focuses on the mechanisms by which cancer cells co-opt and coerce intracellular signalling pathways to promote deregulated cell survival, proliferation and growth. Through the molecular analysis of intracellular signalling pathways, Dr. Guthridge’s laboratory seeks to identify new therapeutic targets in diseases such as leukaemia.

Keywords

Leukaemia, Apoptosis, Signalling, Kinase, Phosphorylation, , cytokine, gene transcription, phosphatidyl inositol 3-kinase,

Publications

Journal Articles

Sandow, J., Jabbour, A., Condina, M., Daunt, C., Stomski, F., Green, B., Riffkin, C., Hoffmann, P., Guthridge, M., Silke, J., Lopez, A., Ekert, P., 2012, Cytokine receptor signaling activates an IKK-dependent phosphorylation of PUMA to prevent cell death, Cell Death and Differentiation [P], vol 19, issue 4, Nature Publishing Group, United Kingdom, pp. 633-641.

Cheah, P., Ramshaw, H., Thomas, P., Toyo-oka, K., Xu, X., Martin, S., Coyle, P., Guthridge, M., Stomski, F., van den Buuse, M., Wynshaw-Boris, A., Lopez, A., Schwarz, Q., 2012, Neurodevelopmental and neuropsychiatric behaviour defects arise from 14-3-3[zeta] deficiency, Molecular Psychiatry [P], vol 17, issue 4, Nature Publishing Group, United Kingdom, pp. 451-466.

Barry, E.F., Felquer, F.A., Powell, J.A., Biggs, L., Stomski, F.C., Urbani, A., Ramshaw, H.S., Hoffmann, P., Wilce, M.C.J., Grimbaldeston, M.A., Lopez, A.F., Guthridge, M.A., 2009, 14-3-3:Shc Scaffolds Integrate Phosphoserine and Phosphotyrosine Signaling to Regulate Phosphatidylinositol 3-Kinase Activation and Cell Survival, Journal of Biological Chemistry, vol 284, issue 18, American Society for Biochemistry and Molecular Biology, Inc, USA, pp. 12080-12090.

Powell, J.A., Thomas, D., Barry, E.F., Kok, C.H., McClure, B.J., Tsykin, A., To, L.B., Brown, A., Lewis, I.D., Herbert, K., Goodall, G.J., Speed, T.P., Asou, N., Jacob, B., Osato, M., Haylock, D.N., Nilsson, S.K., D'Andrea, R.J., Lopex, A.F., Guthridge, M.A., 2009, Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML, Blood [P], vol 114, issue 23, American Society of Hematology, USA, pp. 4859-4870.

Jin, L., Lee, E., Ramshaw, H., Busfield, S., Peoppl, A., Wilkinson, L., Guthridge, M., Thomas, D., Barry, E., Boyd, A., Gearing, D., Vairo, G., Lopez, A., Dick, J., Lock, R., 2009, Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells, Cell Stem Cell [P], vol 5, issue 1, Cell Press, United States, pp. 31-42.

Ramshaw, H.S., Guthridge, M.A., Stomski, F.C., Barry, E.F., Ooms, L.M., Mitchell, C.A., Begley, C.G., Lopez, A.F., 2007, The Shc-binding site of the ?c subunit of the GM-CSF/IL-3/IL-5 receptors is a negative regulator of hematopoiesis, Blood, vol 110, issue 10, American Society of Hematology, Washington DC USA, pp. 3582-3590.

Consulting

Dr. Guthridge consulted for the Commonwealth Serum Laboratories (CSL) between 2004-2009.

Postgraduate Research Supervisions

Current Supervision

Program of Study:

(DOCTORATE BY RESEARCH).

Thesis Title:

Exploring novel molecular targets for the therapy of acute myeloid leukaemia.

Supervisors:

Wei, A (Main), Guthridge, M (Associate).

Program of Study:

(DOCTORATE BY RESEARCH).

Thesis Title:

Roles of the NF-kB transcription factors in Acute Myeloid Leukaemia.

Supervisors:

Gerondakis, S (Main), Guthridge, M (Associate).